IP Library › Granted Patent US 8,247,537

Granted Patent B2

US 8,247,537 · App. 12/515,004 · Granted Aug 21, 2012

Human monoclonal antibodies to BTLA and methods of use

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,247,537
App. No.: 12/515,004
Granted: Aug 21, 2012
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Claims (102)

1. An isolated monoclonal antibody or antigen binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein:

(a) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 26; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 46 and conservative modifications thereof;

(b) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 27; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 47 and conservative modifications thereof;

(c) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 48 and conservative modifications thereof;

(d) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 49 and conservative modifications thereof;

(e) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 29; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 50 and conservative modifications thereof;

(f) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 30; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 51 and conservative modifications thereof;

(g) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 31; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 52 and conservative modifications thereof;

(h) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 82 and conservative modifications thereof;

(i) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 97 and conservative modifications thereof; or

(j) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 89; and the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 92 and conservative modifications thereof; and wherein antibody or antigen-binding portion thereof specifically binds to human BTLA.

2. An isolated monoclonal antibody or antigen binding portion thereof, wherein antibody or antigen-binding portion thereof cross-competes for binding to BTLA with a reference antibody or reference antigen-binding portion thereof comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein:

(a) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 26; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 46;

(b) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 27; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 47;

(c) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 48;

(d) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 28; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 49;

(e) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 29; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 50;

(f) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 30; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 51;

(g) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 31; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 52;

(h) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ 7 ID NO: 82;

(i) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 79; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 97; or

(j) the heavy chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 89; and the light chain variable region CDR3 of the reference antibody or reference antigen-binding portion thereof comprises amino acids having the sequence set forth in SEQ ID NO: 92.

3. The antibody or antigen binding portion thereof, of claim 2 , wherein the reference antibody or reference antigen binding portion thereof contains heavy chain variable region and light chain variable region CDR3 and CDR2 domains selected from the group consisting, of:

(a) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEO ID NO:26; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:46; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 20; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 39;

4. The antibody or antigen binding portion thereof, of claim 3 , wherein the reference antibody or reference antigen binding portion thereof contains heavy chain variable region and light chain variable region CDR3, CDR2, and CDR1 domains selected from the group consisting of:

(a) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:26; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:46; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 20; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 39; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 14; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 32;

(b) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:27; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:47; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 21; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 40; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 33;

(c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:28; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:48; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 41; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 34;

(d) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:28; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:49; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 42; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 35;

(e) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:29; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:50; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEP ID NO: 23; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36;

(f) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:30; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:51; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; and a ligh chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37;

(g) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:31; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:52; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38;

(h) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:79; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:82; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 78; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 81; a heavy chain variable region CDR1 binding portion thereof comprises comprising amino acids having the sequence set forth in SEQ ID NO: 77; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 80;

(i) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:79; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:97; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 78; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 96; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 77; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 95; or

(j) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:89; a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:92; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 88; and a light chain variable region CDR 2 comprising amino acids having the sequence set forth in SEQ ID NO: 91; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 87; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 90.

5. The antibody or antigen-binding portion thereof, of claim 1 , wherein

(a) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 26; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 46 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 20 and conservative modifications thereof; and the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 39 and conservative modifications thereof;

(i) the heavy chain variable region CDR3 comprises amino acids having the se uence set forth in SEQ ID NO: 79; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 97 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 78 and conservative modifications thereof; and the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 96 and conservative modifications thereof; or

6. The antibody or antigen binding portion thereof, of claim 5 , wherein

(a) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 26; the light chain variable region CDR3 comprises amino acids havin the sequence set forth in SEQ ID NO: 46 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 20 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 39 and conservative modifications thereof, the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 14 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 32 and conservative modifications thereof;

(b) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 27; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 47 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 21 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 40 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 15 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 33 and conservative modifications thereof;

(c) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 48 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 22 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 41 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 16 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 34 and conservative modifications thereof;

(d) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 28; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 49 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 22 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 42 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 16 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 35 and conservative modifications thereof;

(e) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 29; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 50 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 23 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 43 and conservative modifications thereof the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 17 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 36 and conservative modifications thereof;

(f) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 30; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 51 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 24 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 44 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 18 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 37 and conservative modifications thereof;

(g) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 31; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 52 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 25 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 45 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 19 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 38 and conservative modifications thereof;

(h) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 82 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 78 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 81 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 77 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 80 and conservative modifications thereof;

(i) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 79; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 97 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 78 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 96 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 77 and conservative modifications thereof; and the light chain variable region CDR 1 comprises amino acids having the sequence set forth in SEQ ID NO: 95 and conservative modifications thereof; or

(j) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 89; the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 92 and conservative modifications thereof; the heavy chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 88 and conservative modifications thereof; the light chain variable region CDR2 comprises amino acids having the sequence set forth in SEQ ID NO: 91 and conservative modifications thereof; the heavy chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 87 and conservative modifications thereof; and the light chain variable region CDR1 comprises amino acids having the sequence set forth in SEQ ID NO: 90 and conservative modifications thereof.

7. The antibody or an antigen-binding portion thereof, of any one of claims 2 - 4 , wherein the reference antibody or reference antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 1; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO 7;

(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 2; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8;

(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 9;

(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 10;

(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 11;

(f) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 12;

(g) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 6; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 13;

(h) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 74; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 75;

(i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 74; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 76; or

(j) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 85; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 86.

8. The antibody or an antigen-binding portion thereof, of claim 7 , wherein the reference antibody or reference antigen-binding portion thereof comprises a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO 9.

9. The antibody or an antigen-binding portion thereof, of claim 7 , wherein the reference antibody or reference antigen-binding portion thereof comprises a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO; 5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO 12.

10. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , comprising:

(a) a heavy chain variable region CDR1 comprising amino acid sequence of SEQ ID NO:16;

(b) a heavy chain variable region CDR2 comprising amino acid sequence of SEQ ID NO:22;

(d) a light chain variable region CDR1 comprising amino acid sequence of SEQ ID NO:34;

(e) a light chain variable region CDR2 comprising amino acid sequence of SEQ ID NO:41; and

(f) a light chain variable region CDR3 comprising amino acid sequence of SEQ ID NO:48;

wherein antibody specifically binds BTLA.

11. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , comprising:

(a) a heavy chain variable region CDR1 comprising amino acid sequence of SEQ ID NO:18;

(b) a heavy chain variable region CDR2 comprising amino acid sequence of SEQ ID NO:24;

(d) a light chain variable region CDR1 comprising amino acid sequence of SEQ ID NO:37;

(e) a light chain variable region CDR2 comprising amino acid sequence of SEQ ID NO:44; and

(f) a light chain variable region CDR3 comprising amino acid sequence of SEQ ID NO:51;

wherein antibody specifically binds BTLA.

12. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO 9.

13. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO 12.

14. The antibody or antigen-binding portion thereof, of claim 1 or 2 , wherein antibody or antigen-binding portion thereof, is linked to a therapeutic agent.

15. The antibody or antigen binding portion thereof, of claim 14 , wherein the therapeutic agent is a cytotoxin.

16. The antibody or antigen binding portion thereof, of claim 14 , wherein the therapeutic agent is a radioactive isotope.

17. The antibody or antigen-binding portion thereof, of claim 1 or 2 , linked to a second functional moiety having a different binding specificity than said antibody or antigen binding portion thereof.

18. A pharmaceutical composition comprising antibody or antigen-binding portion thereof, of claim 1 or 2 , and a pharmaceutically acceptable carrier.

Assignments (2)

MERGER Recorded Mar 19, 2015

From: MEDAREX, L.L.C.

To: E. R. SQUIBB & SONS, L.L.C.

Reel/Frame 035226/0690 →

MERGER Recorded Jun 13, 2013

From: MEDAREX, INC.

To: MEDAREX, L.L.C.

Reel/Frame 030603/0924 →